Novel therapy for children with chronic hormone deficiency provides lifeline for parents

Apr 12, 2019

  • Alkindi® is the first replacement therapy specially designed for infants, children and adolescents with paediatric adrenal insufficiency
  • Adrenal insufficiency is caused by a lack of the stress hormone cortisol – which can be fatal
  • This new therapy, which has been developed by University of Sheffield spin-out company Diurnal, has been granted market authorisation by the European Medicine Agency.

Read more

Recent Blog Posts

What you should know about COVID-19 – updated 24th April

What you should know about COVID-19 – updated 24th April

Guidance from other organizations is continually being issued and we'll do our best to link to them below - please keep checking back here for more updates. UPDATE 24th April 2020 The Lead Editors of the European Journal of Endocrinology (EJE) have commissioned a...